AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21406117 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound plus exercise therapy
Number of subjects: 46
Study 20081257 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous tramadol (100 mg)
Number of subjects: 224
Study 20081257 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 224
Study 17915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide in tablets
Number of subjects: 0
Study 15225828 — intervention group
Group type: EXPERIMENTAL
Intervention: BB genotype
Number of subjects: 0
Study 15225828 — intervention group
Group type: COMPARATOR
Intervention: bb genotype
Number of subjects: 0
Study 15225828 — intervention group
Group type: EXPERIMENTAL
Intervention: TaqI genotypes
Number of subjects: 0
Study 15225828 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR gene polymorphisms defined by ApaI and FokI
Number of subjects: 0
Study 11574379 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation test
Number of subjects: 566
Study 11574379 — intervention group
Group type: COMPARATOR
Intervention: No electrical stimulation test (Control)
Number of subjects: 566
Study 9645715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-enucleation radiation
Number of subjects: 1003
Study 9645715 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1003
Study 7934010 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal encouragement
Number of subjects: 28
Study 7934010 — intervention group
Group type: COMPARATOR
Intervention: No verbal encouragement
Number of subjects: 28
Study 3122600 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.4 mg loading dose followed by 10 micrograms.kg‐1.hr‐1)
Number of subjects: 24
Study 3122600 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone infusion (0.2 mg loading dose followed by 5 micrograms.kg‐1.hr‐1)
Number of subjects: 24
Study 3122600 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (20 ml/hr)
Number of subjects: 24
Study 29307459 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1164
Study 29307459 — intervention group
Group type: COMPARATOR
Intervention: Non-ICD therapy
Number of subjects: 1164
Study 28006855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, prednisone (VMP)
Number of subjects: 479
Study 28006855 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and low-dose dexamethasone (Rd)
Number of subjects: 479
Study 26223257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg + ASA 100 mg
Number of subjects: 213
Study 26223257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg + ASA 100 mg
Number of subjects: 213
Study 26223257 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 213
Study 26223257 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 213
Study 24117909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 74
Study 21173036 — intervention group
Group type: COMPARATOR
Intervention: Heparin-coated CPB (HC-group)
Number of subjects: 24
Study 21173036 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-coated CPB (NC-group)
Number of subjects: 24
Study 18469249 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (M-day)
Number of subjects: 11
Study 18469249 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity physical activity (V-day)
Number of subjects: 11
Study 18469249 — intervention group
Group type: COMPARATOR
Intervention: Control day (C-day)
Number of subjects: 11
Study 20939854 — intervention group
Group type: EXPERIMENTAL
Intervention: white wine
Number of subjects: 21
Study 20939854 — intervention group
Group type: EXPERIMENTAL
Intervention: beer
Number of subjects: 21
Study 20939854 — intervention group
Group type: EXPERIMENTAL
Intervention: rose wine
Number of subjects: 21
Study 20939854 — intervention group
Group type: EXPERIMENTAL
Intervention: red wine
Number of subjects: 21
Study 20939854 — intervention group
Group type: EXPERIMENTAL
Intervention: alcoholic beverages (general)
Number of subjects: 21
Study 16059624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 373
Study 16059624 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 373
Study 16059624 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 373
Study 16059624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 12135019 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole with or without additional antibiotic therapy
Number of subjects: 75
Study 12135019 — intervention group
Group type: COMPARATOR
Intervention: Control group (H. pylori negative patients)
Number of subjects: 75
Study 9435323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 619
Study 9435323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 9435323 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive plasma CMV DNA PCR
Number of subjects: 619
Study 9435323 — intervention group
Group type: EXPERIMENTAL
Intervention: Each log10 increase in baseline CMV DNA load
Number of subjects: 619
Study 8620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton 600mg 4 times daily
Number of subjects: 0
Study 8620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton + Prednisone
Number of subjects: 0
Study 8620666 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 40mg
Number of subjects: 0
Study 2909689 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute surgery (AS: 0 to 3 days after the SAH)
Number of subjects: 216
Study 2909689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate surgery (IS: 4 to 7 days after the SAH)
Number of subjects: 216
Study 2909689 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surgery (LS: 8 days to an indefinite time after the SAH)
Number of subjects: 216
Study 2909689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 216
Study 2909689 — intervention group
Group type: COMPARATOR
Intervention: No nimodipine (placebo + patients not entered into the nimodipine trial)
Number of subjects: 216
Study 2909689 — intervention group
Group type: EXPERIMENTAL
Intervention: Late surgery with nimodipine
Number of subjects: 216
Study 338101 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 338101 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 338101 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 338101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31944870 — intervention group
Group type: EXPERIMENTAL
Intervention: Accurate productions of real words (e.g., 'leaf')
Number of subjects: 40
Study 31944870 — intervention group
Group type: EXPERIMENTAL
Intervention: Misarticulated words (e.g., 'weaf' or 'yeaf')
Number of subjects: 40
Study 31944870 — intervention group
Group type: EXPERIMENTAL
Intervention: Common misarticulation condition
Number of subjects: 40
Study 31944870 — intervention group
Group type: COMPARATOR
Intervention: Uncommon misarticulation condition
Number of subjects: 40
Study 29778325 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 2325
Study 29778325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2325
Study 27710808 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity statin therapy (atorvastatin 80 mg or rosuvastatin 40 mg daily)
Number of subjects: 1641
Study 24836698 — intervention group
Group type: COMPARATOR
Intervention: Conventional BT (CON)
Number of subjects: 32
Study 24836698 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially unloaded BT (PART)
Number of subjects: 32
Study 22503015 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial physical therapy
Number of subjects: 81
Study 22503015 — intervention group
Group type: COMPARATOR
Intervention: Global therapeutic massage
Number of subjects: 81
Study 20085491 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (400 mg twice daily) plus optimized background therapy
Number of subjects: 0
Study 20085491 — intervention group
Group type: COMPARATOR
Intervention: Optimized background therapy alone
Number of subjects: 0
Study 18679601 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI)
Number of subjects: 90
Study 18679601 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control)
Number of subjects: 90
Study 15939026 — intervention group
Group type: EXPERIMENTAL
Intervention: TOE group
Number of subjects: 24
Study 15939026 — intervention group
Group type: EXPERIMENTAL
Intervention: FOOT group
Number of subjects: 24
Study 15939026 — intervention group
Group type: EXPERIMENTAL
Intervention: LEG group
Number of subjects: 24
Study 15939026 — intervention group
Group type: COMPARATOR
Intervention: Full-body display
Number of subjects: 24
Study 12576953 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasal mask ventilation
Number of subjects: 70
Study 12576953 — intervention group
Group type: COMPARATOR
Intervention: Nasal mask ventilation
Number of subjects: 70
Study 12576953 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mask types
Number of subjects: 70
Study 10543335 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine 2 mg twice daily
Number of subjects: 277
Study 10543335 — intervention group
Group type: EXPERIMENTAL
Intervention: oxybutynin 5 mg three times daily
Number of subjects: 277
Study 10543335 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 277
Study 8983874 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine venous pump function test
Number of subjects: 70
Study 1938567 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with four heat treatments
Number of subjects: 1
Study 1938567 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with one heat treatment
Number of subjects: 1
Study 1938567 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone
Number of subjects: 1
Study 1938567 — intervention group
Group type: COMPARATOR
Intervention: Control arm (untreated lesions)
Number of subjects: 1
Study 7278083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg intravenously
Number of subjects: 0
Study 7278083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 200 mg intravenously
Number of subjects: 0
Study 7278083 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine high dose (not specified)
Number of subjects: 0
Study 31476911 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted systolic blood pressure (gSBP) increase by 10 mm Hg
Number of subjects: 5596
Study 29499470 — intervention group
Group type: EXPERIMENTAL
Intervention: English as a Medium of Instruction (EMI) program
Number of subjects: 1288
Study 29499470 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1288
Study 27077973 — intervention group
Group type: EXPERIMENTAL
Intervention: STARFISH program for six weeks
Number of subjects: 23
Study 27077973 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 23
Study 25295663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrogen-rich tablets (2 g per day)
Number of subjects: 36
Study 25295663 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrogen-rich tablets (2 g per day) and topical hydrogen-rich packs (6 times per day for 20 minutes)
Number of subjects: 36
Study 25295663 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional treatment protocol for soft tissue injury)
Number of subjects: 36
Study 22439287 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded parent-proxy ratings of the COPM
Number of subjects: 50
Study 22439287 — intervention group
Group type: COMPARATOR
Intervention: Unblinded parent-proxy ratings of the COPM
Number of subjects: 50
Study 19766645 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFNalpha2a plus RBV 800-1200 mg/day
Number of subjects: 431
Study 19766645 — intervention group
Group type: COMPARATOR
Intervention: PegIFNalpha2b plus RBV 800-1200 mg/day
Number of subjects: 431
Study 17655764 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG + ST-analysis of the fetal ECG
Number of subjects: 5100
Study 17655764 — intervention group
Group type: COMPARATOR
Intervention: CTG + FBS
Number of subjects: 5100
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in AA patients
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in extensive form AA (II group)
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in localized form AA (I group)
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) in family history AA (III group)
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (INF-gamma) between extensive and localized forms of AA
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in AA patients
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in extensive form AA (II group)
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in localized form AA (I group)
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) in family history AA (III group)
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) between extensive and localized forms of AA
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) between extensive form and family history AA
Number of subjects: 30
Study 16052058 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopterin (NPT) between localized form and family history AA
Number of subjects: 30
Study 12131705 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal activity
Number of subjects: 281
Study 12131705 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 281
Study 12237656 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational hypertension
Number of subjects: 58
Study 12237656 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive subjects)
Number of subjects: 58
Study 12237656 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 58
Study 9422572 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 Gy daily fractions
Number of subjects: 57
Study 9422572 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-average and bio-maximum dose (corrected for fraction size)
Number of subjects: 57
Study 9422572 — intervention group
Group type: COMPARATOR
Intervention: uncorrected dose distributions
Number of subjects: 57
Study 8024137 — intervention group
Group type: EXPERIMENTAL
Intervention: Head immobilization (passive immobilization with the head held flat against a rigid board)
Number of subjects: 31
Study 8024137 — intervention group
Group type: COMPARATOR
Intervention: No stabilization
Number of subjects: 31
Study 2637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrushing-instruction (individual training in horizontal scrubbing)
Number of subjects: 64
Study 2637357 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive (promise of a special prize for brushing well)
Number of subjects: 64
Study 2637357 — intervention group
Group type: COMPARATOR
Intervention: No-instruction group
Number of subjects: 64
Study 2637357 — intervention group
Group type: COMPARATOR
Intervention: No-incentive condition
Number of subjects: 64
Study 871980 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 rads of cobalt‐60 gamma irradiation a few hours before excision of the lesion
Number of subjects: 125
Study 871980 — intervention group
Group type: COMPARATOR
Intervention: No irradiation (control group)
Number of subjects: 125
Study 31356373 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE)
Number of subjects: 200
Study 31356373 — intervention group
Group type: COMPARATOR
Intervention: Control as usual (CAU)
Number of subjects: 200
Study 28328347 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL830 40 IU/kg twice weekly
Number of subjects: 90
Study 28328347 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL830 60 IU/kg twice weekly
Number of subjects: 90
Study 28328347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25833063 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (4 ml/kg body weight, 0.48 g/kg of alcohol 12%, corresponding to 2-3 glasses/daily) and extra-virgin olive oil (treatment A)
Number of subjects: 20
Study 25833063 — intervention group
Group type: COMPARATOR
Intervention: Extra-virgin olive oil alone (treatment B)
Number of subjects: 20
Study 25833063 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine and extra-virgin olive oil (treatment A)
Number of subjects: 20
Study 23517291 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10 mg/day
Number of subjects: 673
Study 23517291 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 673
Study 23517291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study 23517291 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10 mg/day and 50 mg/day
Number of subjects: 673
Study 22586828 — intervention group
Group type: COMPARATOR
Intervention: Heel lift of six mm or more under the right foot
Number of subjects: 30
Study 22586828 — intervention group
Group type: COMPARATOR
Intervention: Heel lift of four mm or more under the left foot
Number of subjects: 30
Study 22586828 — intervention group
Group type: COMPARATOR
Intervention: Heel lift of eight mm or more under the right foot
Number of subjects: 30
Study 22586828 — intervention group
Group type: COMPARATOR
Intervention: Heel lift of seven mm or more under the left foot
Number of subjects: 30
Study 19524243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (3-4 times per week for 6 months at 50% of maximal oxygen consumption)
Number of subjects: 267
Study 19524243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 267
Study 16621868 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe (Group A)
Number of subjects: 60
Study 16621868 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe as an add-on to 20 mg/day simvastatin (Group B)
Number of subjects: 60
Study 16621868 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose escalation from 10 to 40 mg/day atorvastatin (Group C)
Number of subjects: 60
Study 16621868 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo monotherapy with 40 mg/day atorvastatin (Group D)
Number of subjects: 60
Study 23570208 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Buddy (interactive device for asthma self-management)
Number of subjects: 134
Study 23570208 — intervention group
Group type: COMPARATOR
Intervention: Asthma diary (control group)
Number of subjects: 134
Study 11371418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Splint (MAS)
Number of subjects: 28
Study 11371418 — intervention group
Group type: COMPARATOR
Intervention: Control oral plate (A)
Number of subjects: 28
Study 9296410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 0, 25, 50, or 75 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 9296410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 50-75 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 9296410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion of 25-50 microg x kg(‐1) x min(‐1) in combination with alfentanil infusion of 0.2-0.4 microg x kg(‐1) x min(‐1)
Number of subjects: 72
Study 9296410 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sedation with propofol
Number of subjects: 72
Study 8289986 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g elemental calcium per day
Number of subjects: 23
Study 8289986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2825369 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hyperthermia/radiotherapy
Number of subjects: 158
Study 2825369 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 158
Study 2825369 — intervention group
Group type: COMPARATOR
Intervention: Planned postoperative radiation without hyperthermia
Number of subjects: 158
Study 2825369 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone in cases of inoperability
Number of subjects: 158
Study 31714430 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-32γ
Number of subjects: 0
Study 31714430 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-32α
Number of subjects: 0
Study 31714430 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-32β
Number of subjects: 0
Study 31714430 — intervention group
Group type: COMPARATOR
Intervention: IL-32α and IL-32β
Number of subjects: 0
Study 30137657 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-based website (IG)
Number of subjects: 337
Study 30137657 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UCG)
Number of subjects: 337
Study 26111989 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) with quadriceps strengthening exercise (QSE)
Number of subjects: 39
Study 26111989 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps strengthening exercise (QSE) alone
Number of subjects: 39
Study 24507630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for PTSD (n = 30)
Number of subjects: 59
Study 24507630 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (n = 29)
Number of subjects: 59
Study 22293542 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Number of subjects: 255
Study 22293542 — intervention group
Group type: COMPARATOR
Intervention: atazanavir
Number of subjects: 255
Study 22293542 — intervention group
Group type: EXPERIMENTAL
Intervention: both arms
Number of subjects: 255
Study 20854144 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice-daily
Number of subjects: 600